Anavex Life Sciences Corp. (NASDAQ:AVXL) shares, rose in value on Thursday, 06/23/22, with the stock price up by 10.47% to the previous day’s close as strong demand from buyers drove the stock to $10.45.
Actively observing the price movement in the last trading, the stock closed the session at $9.46, falling within a range of $9.80 and $10.485. The value of beta (5-year monthly) was 0.73. Referring to stock’s 52-week performance, its high was $31.50, and the low was $7.13. On the whole, AVXL has fluctuated by 12.73% over the past month.
With the market capitalization of Anavex Life Sciences Corp. currently standing at about $737.25 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 09, 2022 – Feb 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.17, which is expected to increase to -$0.13 for fiscal year -$0.65 and then to about -$0.73 by fiscal year 2023. Data indicates that the EPS growth is expected to be -20.40% in 2023, while the next year’s EPS growth is forecast to be -12.30%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that AVXL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AVXL currently trading nearly 21.52% and 15.30% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.07, while the 7-day volatility ratio is showing 9.02% which for the 30-day chart, stands at 7.81%. Furthermore, Anavex Life Sciences Corp. (AVXL)’s beta value is 0.97, and its average true range (ATR) is 0.75.
A comparison of Anavex Life Sciences Corp. (AVXL) with its peers suggests the former has fared considerably weaker in the market. AVXL showed an intraday change of 10.47% in last session, and over the past year, it shrunk by -56.87%%. In comparison, Ligand Pharmaceuticals Incorporated (LGND) has moved higher at 9.11% on the day and was down -31.50% over the past 12 months. On the other hand, the price of BioCryst Pharmaceuticals Inc. (BCRX) has risen 7.17% on the day. The stock, however, is off -40.14% from where it was a year ago. Additionally, there is a loss of -1.80% for Palatin Technologies Inc. (PTN) in last trading while the stock has seen an overall depriciation of -49.08%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.95%. Meanwhile, the Dow Jones Industrial Improved by 0.64%.
Data on historical trading for Anavex Life Sciences Corp. (NASDAQ:AVXL) indicates that the trading volumes over the past 3 months, they’ve averaged 876.62K. According to company’s latest data on outstanding shares, there are 76.25 million shares outstanding.
Nearly 1.70% of Anavex Life Sciences Corp.’s shares belong to company insiders and institutional investors own 32.90% of the company’s shares. The stock has fallen by -39.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AVXL stock heading into the next quarter.